GlassScriptPhysician profile
Armando M Gonzalez
NPI 1003827692
$3,371.13
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $875 · 2021: $894 · 2022: $224 · 2023: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $509.38 | 2019-2021 | |
| Amgen INC. | $417.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $382.48 | 2019-2023 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.76 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $253.50 | 2019-2022 | |
| Glaxosmithkline, LLC. | $214.12 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $184.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.38 | 2023 | |
| Dynasplint Systems INC. | $144.54 | 2021 | |
| Merck Sharp & Dohme LLC | $144.02 | 2019-2021 | |
| Abbott Laboratories | $80.44 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $77.62 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $73.02 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $59.62 | 2022 | |
| Pfizer INC. | $46.62 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $45.17 | 2023 | Quviviq |
| Medicure Pharma INC. | $32.27 | 2021 | |
| Esperion Therapeutics, INC. | $32.04 | 2021 | |
| Biogen, INC. | $30.97 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $29.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.12 | 2019-2023 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $24.49 | 2019-2020 | |
| Eisai INC. | $21.23 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.63 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.88 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.43 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $12.11 | 2020 | |
| Abbvie INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.